VRTX · 10-Q · 2026Q2 · Full report

Reimbursement and Payer Mix

VERTEX PHARMACEUTICALS INC / MA · 2026-08-04 · Importance 37 · Surprise 42 · In source text

Vertex secured ALYFTREK reimbursement in four additional countries during the second quarter of 2026, bringing reimbursement coverage to 25 countries, and signed a letter of intent with the Pan-Canadian Pharmaceutical Alliance for eligible Canadian patients at least six years old. Two additional major pharmacy benefit managers agreed to Medicare Part D coverage for JOURNAVX, giving reimbursed access through three of the four major Medicare Part D managers. Twenty-three states cover JOURNAVX through Medicaid, and approximately 260 million people have reimbursed access across commercial and government payers. Vertex expects continued investment in reimbursement activities for CF medicines, CASGEVY, JOURNAVX and future pipeline products.

Key facts

• Signed letter of intent with the Pan-Canadian Pharmaceutical Alliance for ALYFTREK reimbursement for eligible patients six years and older in Canada source
• Secured reimbursement for CASGEVY in May 2026 for eligible patients 12 years and older with SCD or TDT in Germany source
• Reached agreements with two additional major pharmacy benefit managers for Medicare Part D coverage of JOURNAVX, resulting in seniors covered by three of the four major Medicare Part D managers having reimbursed access source
• ALYFTREK reimbursement secured in four additional countries in Q2 2026 including Spain, bringing total reimbursed countries to 25 source
• Twenty-three states provide Medicaid coverage for JOURNAVX; approximately 260 million individuals have reimbursed access to JOURNAVX across commercial and government payers source

Impact estimates